PTK2抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: NIH/3T3 cells, Primary antibody: P07989(PTK2 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

The PTK2 antibody targets Protein Tyrosine Kinase 2 (PTK2), commonly known as Focal Adhesion Kinase (FAK), a non-receptor cytoplasmic tyrosine kinase critical in regulating cellular adhesion, migration, proliferation, and survival. FAK integrates signals from extracellular matrix interactions via integrins and growth factor receptors, influencing downstream pathways like PI3K/AKT and MAPK. Its structure includes an N-terminal FERM domain, a central kinase domain, and C-terminal focal adhesion-targeting (FAT) region. Autophosphorylation at tyrosine residue Y397 creates a binding site for Src-family kinases, amplifying signaling cascades.

PTK2 antibodies are essential tools in studying FAK's role in physiological and pathological processes, particularly cancer. Overexpression or hyperactivation of FAK correlates with tumor progression, metastasis, and poor prognosis, making it a therapeutic target. These antibodies enable detection of FAK expression levels, phosphorylation status (e.g., Y397. Y576/577), and localization in tissues or cell lines using techniques like Western blot, immunohistochemistry, and immunofluorescence. Researchers also utilize them to explore FAK's involvement in embryonic development, wound healing, and angiogenesis. In drug discovery, PTK2 antibodies help assess efficacy of FAK inhibitors in preclinical models. Their specificity varies, with some recognizing total FAK protein and others targeting phospho-specific epitopes, allowing precise investigation of signaling dynamics. Proper validation ensures reliability in experimental and potential diagnostic applications.